Our leadership team brings diverse experience in research, clinical development, business operations, and patient care to Seagen. Their expertise and guidance are critical to advancing our mission to make a meaningful difference in cancer care.
Dr. Siegall co-founded Seagen in 1998 with a vision to improve the lives of people with cancer by developing targeted therapies to treat major unmet needs. A scientist by training, he built a foundation based on a unique science-driven culture, successful drug discovery and development, and a passion for helping patients. Today, Seagen has three FDA-approved medicines and leads the field in antibody–drug conjugate (ADC) technology and development.
Prior to founding Seagen, Dr. Siegall held positions at Bristol Myers Squibb Pharmaceutical Research Institute, the National Institutes of Health, and the National Cancer Institute. He has authored more than 70 publications and holds 15 patents. Dr. Siegall has been recognized as an Ernst & Young Entrepreneur of the Year and the Dealmaker of the Year by the Puget Sound Business Journal.
Dr. Siegall holds a Ph.D. in Genetics from George Washington University and a B.S. in Zoology from the University of Maryland. He serves as a member of the board of directors of Nurix Therapeutics, Inc. and Washington Roundtable.
Dr. Baker has served on the Board of Directors for Seagen since July 2003 and as our lead independent director since February 2005. He is also the founder of Baker Bros. Advisors LP, an advisory firm focused on investments in life science and biotechnology companies. As a board member and investor in many successful biotechnology companies, Dr. Baker’s experience and vision in investment and company building adds significant value to Seagen’s strategy.
Dr. Baker holds a B.S. and a Ph.D. in Immunology from Stanford University, where he also completed two years of medical school. He serves as a member of the board of directors of Kiniksa Pharmaceuticals, Ltd., Kodiak Sciences Inc., IGM Biosciences, Inc., and Talis Biomedical Corporation.
Mr. Gryska joined our Board of Directors in March 2005. With many years of experience as a senior financial executive at life sciences and biotechnology companies, he brings expertise in financing, global expansion, and other strategic transactions to our board. Mr. Gryska is the chair of our Audit Committee, utilizing his extensive knowledge of accounting principles, financial reporting rules and regulations, tax compliance, and financial reporting processes at publicly traded corporations.
Throughout his career, Mr. Gryska served as a Chief Financial Officer at Incyte Corporation, Celgene Corporation, Scios Inc., and Cardiac Pathways Corporation. He was the Executive Vice President and Chief Financial Officer of Incyte Corporation.
Mr. Gryska holds an M.B.A. from Golden Gate University and a B.A. in Accounting and Finance from Loyola University. He serves as a member of the board of directors for Aerie Pharmaceuticals, Inc.
Dr. Lippman has served on the board of Seagen since June 2000. His extensive experience in patient care and oncology research brings a critical perspective to our development of targeted oncology therapies.
Dr. Lippman is a Professor of Oncology at Georgetown University Medical Center’s Lombardi Comprehensive Cancer Center. Previously, he was the Kathleen and Stanley Glaser Professor of Medicine and Chairman of the Department of Medicine at the University of Miami Leonard M. Miller School of Medicine and the Deputy Director of the Sylvester Comprehensive Cancer Center. He has authored more than 400 peer-reviewed publications and one of the standard texts on breast cancer.
Dr. Lippman holds an M.D. from Yale, where he was elected to Alpha Omega Alpha, and a B.A. from Cornell University, where he graduated magna cum laude.
Dr. Love joined our Board of Directors in August 2020. With more than two decades of leadership and management experience in the pharmaceutical industry, in addition to prior experience as a practicing physician, Dr. Love brings both strong business expertise and knowledge of patient perspectives to our Board of Directors.
Dr. Love is the President and Chief Executive Officer of Global Blood Therapeutics, Inc. Previously, he was Executive Vice President, Research and Development and Technical Operations at Onyx Pharmaceuticals, Inc.
Dr. Love holds a B.A. in Molecular Biology from Haverford College and an M.D. from Yale Medical School. Dr. Love also serves on the boards of Global Blood Therapeutics, Inc. and Royalty Pharma plc.
Mr. Orwin joined the Seagen Board of Directors in January 2014. With many years of experience as a senior executive at leading pharmaceutical and biotechnology companies, he brings a strong understanding of the industry and the challenges we must meet to continue developing and commercializing product candidates.
Mr. Orwin is the President and Chief Executive Officer of Atreca, Inc. Previously, he was the Chief Executive Officer of Relypsa, Inc., now an affiliate of Vifor Pharma AG. Mr. Orwin also held multiple leadership roles at Affymax, Inc., including Chief Executive Officer, President, and Chief Operating Officer. Earlier in his career, he led the BioOncology Business Unit at Genentech, Inc. and was the Franchise Vice President of Tibotec Therapeutics at Johnson & Johnson.
Mr. Orwin holds an M.B.A. from the Stern School of Business at New York University and a B.A. in Economics from Rutgers University. He serves as a member of the board of directors for Atreca, Inc. and Travere Therapeutics, Inc.
Dr. Seth joined our Board of Directors in March 2018. With more than 20 years of global experience in the biotechnology industry, she brings a breadth of expertise in drug development, commercialization, and international operations to Seagen.
Dr. Seth is the Chief Executive Officer and President of Proneurotech Inc., a biopharmaceutical company focused on the discovery of novel neuroprotective drugs. Previously, she was Chief Operating Officer of Vir Biotechnology, Inc. and the Senior Vice President and Global Head of the Biosimilars Global Business Unit at Biogen Inc. Before joining Biogen, Dr. Seth was a management consultant in the healthcare industry.
Dr. Seth earned her Ph.D. in Biochemistry and Molecular Biology from the University of Massachusetts Medical School and completed post-doctoral research at Harvard University in Immunology and Structural Biology. She is a graduate of Harvard Business School’s Advanced Management Program (AMP) and has served as a guest lecturer at Harvard Business School and Harvard Medical School. Dr. Seth serves as a member of the board of directors for Bio-Techne Corporation.
Dr. Simonian is a seasoned senior executive in biotechnology who joined the Seagen Board of Directors in March 2012. She possesses a deep understanding of the biotechnology industry and the development and commercialization of product candidates. As a physician, Dr. Simonian also brings important insight into patient perspectives to our Board of Directors.
Dr. Simonian is the Chief Executive Officer of Syros Pharmaceuticals, Inc. Previously, she was the Chief Medical Officer at Millennium Pharmaceuticals, Inc. and the Vice President of Clinical Development at Biogen.
Dr. Simonian holds an M.D. from the University of Pennsylvania Medical School and a B.A. in Biology from Princeton University. She serves as a member of the board of directors for Syros Pharmaceuticals, Inc.
Mr. Welch has served on the Board of Directors for Seagen since June 2007. With a background in global commercial development and experience as a senior executive at biotechnology companies, he contributes invaluable strategic insight to our senior management and Board of Directors.
Previously, Mr. Welch was an Executive Partner at Sofinnova Ventures and the Chairman and Chief Executive Officer of two publicly traded biotechnology companies, InterMune, Inc. and Triangle Pharmaceuticals, Inc.
Mr. Welch holds an M.B.A. from the University of North Carolina and a B.A. from the University of Miami. He serves as Chairman of the Board for Ultragenyx Pharmaceuticals Inc., as well as Nuvation Bio Inc.